It has been shown that B-NHL patients on anti-CD20 antibody monotherapy or anti-CD19 CAR T treatment are able to mount potent S-specific CD4+ and CD8+ T lymphocyte responses following COVID-19 mRNA vaccination, despite impaired humoral responses [29,30]. Here, CD8A is linked to COVID-19.